Business Wire03.13.20
Surmodics Inc., a provider of medical device and in-vitro diagnostic technologies to the healthcare industry, announced that Nusrath Sultana, M.D., has joined Surmodics as vice president, Clinical Affairs.
“We are fortunate to have someone of Nusrath’s caliber joining the Surmodics team,” said Gary Maharaj, president and CEO of Surmodics. "She brings a wealth of experience and a proven track record of success that make her the ideal person to lead clinical affairs. Nusrath’s leadership will be critical to our clinical strategy, and the design and conduct of effective clinical trials with the highest ethical and safety standards.”
Sultana brings more than 20 years of medical affairs, medtech, and healthcare experience. Prior to joining Surmodics, she served as senior director, Global Medical Affairs, at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Sultana was responsible for the development of medical affairs infrastructure and provided leadership, oversight and strategic direction for core medical affairs activities. Prior to her time at Edwards Lifesciences, Sultana held numerous positions—most recently senior director, Global Clinical Operations—at St. Jude Medical Inc. She earned her M.D. from Deccan College of Medical Science in Hyderabad, India, and an MBA in medical group management from the University of St. Thomas in St. Paul, Minn.
"I am excited to join the Surmodics team and look forward to helping the company achieve its vision,” said Sultana. “The ongoing clinical initiatives and multiple product platforms have the potential to provide meaningful benefits for patients undergoing peripheral vascular treatment. I am honored to be a part of this journey.”
As vice president, Clinical Affairs, Sultana will be responsible for executive oversight and overall management of the company’s clinical study programs and clinical trial design and execution. She will be a member of the senior leadership team reporting directly to Maharaj.
Surmodics recently reported first-quarter FY20 revenue of $22.6 million, a 2 percent increase compared with $22.2 million in the prior-year period. Medical Device revenue was $17.4 million in the first quarter of fiscal 2020, as compared with $17.3 million in the year-ago period, an increase of 1 percent. Revenue in the first quarter includes $1.3 million from our SurVeilTM agreement with Abbott, as compared with $2.4 million in the prior-year quarter. In Vitro Diagnostics revenue was $5.2 million for the first quarter of fiscal 2020 as compared with $5 million in the same prior-year quarter, an increase of 5 percent.
“We are fortunate to have someone of Nusrath’s caliber joining the Surmodics team,” said Gary Maharaj, president and CEO of Surmodics. "She brings a wealth of experience and a proven track record of success that make her the ideal person to lead clinical affairs. Nusrath’s leadership will be critical to our clinical strategy, and the design and conduct of effective clinical trials with the highest ethical and safety standards.”
Sultana brings more than 20 years of medical affairs, medtech, and healthcare experience. Prior to joining Surmodics, she served as senior director, Global Medical Affairs, at Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Sultana was responsible for the development of medical affairs infrastructure and provided leadership, oversight and strategic direction for core medical affairs activities. Prior to her time at Edwards Lifesciences, Sultana held numerous positions—most recently senior director, Global Clinical Operations—at St. Jude Medical Inc. She earned her M.D. from Deccan College of Medical Science in Hyderabad, India, and an MBA in medical group management from the University of St. Thomas in St. Paul, Minn.
"I am excited to join the Surmodics team and look forward to helping the company achieve its vision,” said Sultana. “The ongoing clinical initiatives and multiple product platforms have the potential to provide meaningful benefits for patients undergoing peripheral vascular treatment. I am honored to be a part of this journey.”
As vice president, Clinical Affairs, Sultana will be responsible for executive oversight and overall management of the company’s clinical study programs and clinical trial design and execution. She will be a member of the senior leadership team reporting directly to Maharaj.
Surmodics recently reported first-quarter FY20 revenue of $22.6 million, a 2 percent increase compared with $22.2 million in the prior-year period. Medical Device revenue was $17.4 million in the first quarter of fiscal 2020, as compared with $17.3 million in the year-ago period, an increase of 1 percent. Revenue in the first quarter includes $1.3 million from our SurVeilTM agreement with Abbott, as compared with $2.4 million in the prior-year quarter. In Vitro Diagnostics revenue was $5.2 million for the first quarter of fiscal 2020 as compared with $5 million in the same prior-year quarter, an increase of 5 percent.